On June 4, 2019 NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, reported it has appointed Edwina Baskin-Bey, M.D. as its new CMO (Press release, Nanobiotix, JUN 4, 2019, View Source [SID1234536862]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Baskin-Bey brings over 18 years of oncology clinical development and basic science experience in academia and industry, most recently serving as CMO of North Carolina-based oncology start-up, Innocrin Pharmaceuticals. As a member of the Executive Team at Innocrin, Dr. Baskin-Bey led development and implementation of the overall clinical and corporate strategy from phase I to phase III. She was responsible for the Medical, Regulatory, Pharmacovigilance, Clinical Operations, Biostatistics, and Data Management functions.
Dr. Baskin-Bey joined Innocrin from Janssen Oncology of Johnson & Johnson, where she was charged with leading both early-and late-stage oncology global development programs for in-licensed products from Aragon and Tesaro, apalutamide and niraparib. Previously, she worked for more than six years at Astellas Pharma. At Astellas, BV, Netherlands Headquarters, Dr. Baskin-Bey, was responsible for several early-stage oncology programs, most notably, she co-led with the alliance partner, Medivation, the global development strategy for the in-licensed product enzalutamide, leading to FDA approval, EMA approval, and label expansions. Also while at Astellas, she served at the UK Headquarters as head of European Medical Affairs, where she was responsible for the launch of enzalutamide in Europe.
Dr. Baskin-Bey currently serves as an independent board member for Catalyst Clinical Research, LLC, in North Carolina. Dr. Baskin-Bey obtained her bachelor’s degree from Hunter College in New York, and earned her medical degree at Mount Sinai/New York University (NYU) School of Medicine. She trained in general surgery and oncology for seven years at The Mayo Clinic in Rochester, MN, and in basic science research principles at the National Institute of Health (NIH).
Dr. Baskin-Bey succeeds accomplished Nanobiotix CMO, Elsa Borghi, M.D. Dr. Borghi will remain with the company in a key leadership role focused on early development and innovation